At a glance
- Originator Boehringer Ingelheim (Canada)
- Class Antivirals
- Mechanism of Action HIV protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 30 Nov 2000 Discontinued-Preclinical for HIV infections treatment in Canada (PO)
- 10 Aug 1999 No-Development-Reported for HIV infections treatment in Canada (PO)
- 09 Sep 1997 Preclinical development for HIV infections treatment in Canada (PO)